Compare AngloGold Ashanti Limited (AU) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Incyte Corporation — how do they compare? AngloGold Ashanti Limited trades at $98.47 (market cap $49.28B), while Incyte Corporation trades at $120.96 (market cap $24.54B). The key difference: AngloGold Ashanti Limited is far larger — about 2× Incyte Corporation's market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AU | INCY | |
|---|---|---|
Market Cap | $49.28B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $129.93 |
52-Week Low | $52.15 | $81.61 |
Enterprise Value | $48.29B | $20.04B |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $97.25, up 1.07% today, with a bullish technical signal from moving averages but overbought RSI readings. Strong fundamentals include a 26.64% net margin for 2025, robust free cash flow growth, and a $2 billion buyback program. Recent Q2 2026 earnings beat expectations, though Q4 2025 and Q2 2026 were misses. Analyst consensus is bullish with a $120.33 price target, and institutional buying has been noted in recent filings.
Outlook remains positive due to high gold prices, production growth, and shareholder returns, but risks include operational disruptions, inflation pressures, and volatile gold markets. The stock offers value with a P/E of 13.06 and strong profitability, yet investors should monitor cost inflation and geopolitical factors affecting mining operations.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
